Drug intelligence / Profile preview

GC503

Development stage: Discontinued
Lead developer: Gracell Biotechnologies
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

GC503 is an autologous CAR-T cell therapy developed by Gracell Biotechnologies targeting mesothelin (MSLN), a cell surface protein highly expressed in various solid tumors. The drug was designed as a mesothelin inhibitor, aiming to treat patients with mesothelin-positive solid tumors. It was part of Gracell's early-stage pipeline and reached the discovery phase, with initial investigator-initiated trials (IIT) conducted in China. However, the program has since been discontinued as part of a strategic reprioritization to focus on more advanced or differentiated candidates within Gracell’s portfolio[1][2][3][7].

Targets

Mesothelin

Beyond the preview

Go deeper on GC503.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GC503.

Explore the full profile